Could a common diabetes drug repair heart damage in atrial fibrillation?

NCT ID NCT05993897

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether dapagliflozin, a drug typically used for diabetes, can improve the structure and function of the heart's left atrium in people with paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes). Researchers will measure changes in heart size and strain using imaging, regardless of whether participants have diabetes. The trial involves 60 adults aged 18–60 with normal to mildly enlarged left atria and adequate kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dapagliflozin (SGLT2 inhibitor)
What this could lead to
If successful, this could show that SGLT2 inhibitors help reverse heart damage in atrial fibrillation, potentially reducing complications like stroke and heart failure.
What could go wrong
This is a small, early-phase study with 60 participants, so results may not apply broadly. The drug may not improve heart remodeling or could cause side effects like dehydration or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aswan university

    Aswān, Aswan Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.